Morio S, Oh H, Kogure K, Ishii H, Ishii A, Nakaseko C, Ikegami T, Kawano E, Matsuura Y, Nishimura M
Second Department of Internal Medicine, Chiba University School of Medicine.
Rinsho Ketsueki. 1994 Sep;35(9):846-52.
We performed retrospective analysis of hepatic veno-occlusive disease (VOD) in 57 cases with leukemia after allogeneic bone marrow transplantation (BMT). Prostaglandin E1 (PGE1) was used to prevent VOD in 8 cases at a dose of 0.3 micrograms/kg/hr from day -8 to day 30. No VOD was noted in the PGE1 group, while the incidence of VOD was 8/49 (16.3%) in the non PGE1 group. In twelve patients with pretransplant liver dysfunction, VOD was noted in 0/3 in the PGE1 group and 4/9 (44.4%) in the non PGE1 group, respectively. However, prophylactic effects of PGE1 on VOD is not significant in this study, so further studies are needed to determine the efficacy of PGE1. One of 8 patients with PGE1 prophylaxis had edema and erythema on extremities, however, severe toxicity was not experienced.
我们对57例异基因骨髓移植（BMT）后发生肝静脉闭塞病（VOD）的白血病患者进行了回顾性分析。8例患者从移植前第8天至第30天使用前列腺素E1（PGE1）预防VOD，剂量为0.3微克/千克/小时。PGE1组未发现VOD，而非PGE1组VOD发生率为8/49（16.3%）。在12例移植前有肝功能不全的患者中，PGE1组0/3发生VOD，非PGE1组4/9（44.4%）发生VOD。然而，本研究中PGE1对VOD的预防作用不显著，因此需要进一步研究以确定PGE1的疗效。8例接受PGE1预防的患者中有1例出现四肢水肿和红斑，但未出现严重毒性反应。
